Skip to content

ViewRay Systems, Inc. is a medical technology company based in Cleveland, Ohio, known for its MRIdian A3i MRI-guided radiation therapy system.

Last updated September 1, 2026

AI crawler reads

2requests

1companies
  • Anthropic2
Profile
2
Controversies
0
JSON · MD
0
First read
Nov 4, 2026
Latest read
Nov 4, 2026

From this site's server log

Overview

ViewRay Systems, Inc. is a medical technology company based in Cleveland, Ohio. The company offers the MRIdian A3i, an MRI-guided radiation therapy system. The system is described as the first MR-guided radiotherapy system with peer-reviewed evidence demonstrating reduced side effects and extended survival. The company's headquarters is located at 2 Thermo Fisher Way, Oakwood Village, Ohio 44146.

History

ViewRay Systems, Inc. is a medical technology company based in Cleveland, Ohio. The company offers the MRIdian A3i, an MRI-guided radiation therapy system. The system is described as the first MR-guided radiotherapy system with peer-reviewed evidence demonstrating reduced side effects and extended survival. The company's headquarters is located at 2 Thermo Fisher Way, Oakwood Village, Ohio 44146.

Products and positioning

  • MRIdian A3i

    MRI-guided radiation therapy system

Recent events

  • Reported

    ViewRay prices public stock offering[4]

    ViewRay announced the pricing of an underwritten public offering of 12.5 million common shares at $5.60 per share, for gross proceeds of $70 million before expenses. The offering was expected to close on or about November 19, 2021, subject to customary conditions.

  • Reported

    Elekta and ViewRay announced MR-guided radiation therapy collaboration[5]

    Elekta announced that it had signed a non-binding memorandum of understanding with ViewRay to advance knowledge and application of MR-guided radiation therapy. The companies said the collaboration was subject to definitive documentation.

  • Reported

    ViewRay prices public stock offering[6]

    ViewRay announced pricing for an underwritten public offering of 41,550,000 shares at $3.13 per share, for gross proceeds of approximately $130.1 million before expenses.

  • Reported

    ViewRay and Medtronic announced a clinical collaboration memorandum[7]

    ViewRay announced that it signed a non-binding memorandum of understanding with Medtronic to enter into a clinical collaboration, including exploring clinical benefits of the MRIdian MR-guided radiation therapy system. Medtronic committed to invest in a minority interest in ViewRay, subject to a commitment agreement.

  • Reported

    ViewRay and Elekta announced a collaboration memorandum[7]

    ViewRay announced that it signed a non-binding memorandum of understanding with Elekta for collaboration to advance knowledge and use of MR-guided radiation therapy. The collaboration is subject to execution of definitive documentation.

Read more

Sources8 sources

Cite this profile: Cite the canonical profile. /brand-wiki/viewray · Editorial policy · How profiles are compiled